In the 40 years since the Journal was first published there have been eight Editors-in-Chief (EiCs). The job is demanding, unrelenting and, at the same time, a creative experience and a great privilege. All EiCs have had one thing in common-enthusiasm and real commitment to their appointment. Orchestrating an editorial team, the publishers and the support staff in the Editorial Office plus the various Advisors and Editorial Boards requires constant consideration and attention to ensure that there is a smooth flow of papers from receipt to review, editorial refinement and publication. The EiC also has to encourage the Editorial Board and manage feedback on the performance of the Journal and its future plans. The pressure from anxious authors and from competing journals leaves little time for relaxation! Each EiC has brought their own flare and creative energy to the Journal. It is interesting to observe the 'shape' of the Journal over the years in terms of its sectional composition. The very first edition created a blueprint for subsequent developments. This included Leading Articles, Original Articles, Correspondence and Book Reviews. Subsequent editions added Short Reports, later defined as Brief Reports. The inclusion of commissioned Reviews was welcomed and, together with the Leading Articles, provided an opportunity to highlight topical and significant developments in antimicrobial chemotherapy. They also proved a constant challenge to the EiC to ensure a steady flow of appropriate material! This required regular attendance at national and international meetings as well as scanning the literature to support such articles. Another sectional development of note is the inclusion of occasional articles under the heading of For Debate for subjects where controversy exists.
While the Society and the Journal are intimately connected, the EiC has to ensure that the broader scientific and clinical community are well served by the publication and to resist the criticism of parochialism. A society newsletter serves this purpose much more effectively. Nonetheless, over the years the symbiosis between the Society and the Journal has been, and continues to be, mutually creative. Examples include the publication of the annual Garrod Lecture and Working Party (WP) Reports, an area in which the Society has proved particularly energetic and influential. While the Journal has been the repository for the publication of the majority of these Reports, some have been more appropriately published elsewhere as a result of discussions between the WP lead, the Society and the Journal.
Other initiatives published by the Journal have included Society or Journal-specific symposia. These are often designed around topics and themes suitable for review-style publication or have focused on information concerning a novel therapeutic agent or therapeutic area. The close links between the organizers of the symposium and the invited speakers/authors has been one of the strengths of the Journal whereby an editorial team working on site at the meeting reviews, discusses and edits the various manuscripts with input from the authors. I am unsure whether this process is unique to the Journal, but it certainly resulted in the speedy processing and publication of the outputs of such meetings, something that is usually appreciated by authors, sponsors and the readership. To facilitate this particular activity requires cultivating a close working relationship between the Journal and the Society.
The desire of the Society and the Journal to be inclusive of both basic laboratory research and clinical practice has influenced the choice of Society President and EiC. Likewise, the Journal has made efforts to capture this breadth of outputs in its selection of papers for publication. However, it has always been a challenge to ensure an adequate flow of clinical papers. The selection of topics when commissioning Leading Articles and Reviews has, in part, helped to address this issue. More specifically, the inclusion of the section entitled Antimicrobial Practice sent a strong signal to encourage more original research articles in this area.
The evolution in the content of published material over the years has largely reflected the dynamics in the science and clinical practice of managing infection in man. In the early days the support from Society members in submitting their original material to the Journal was extremely helpful in establishing the Journal as a key player in its field. This loyalty of members has been emulated in rival publications, such as Clinical Microbiology and Infection. Unlike the basket of journals published by the American Society for Microbiology, the Journal is owned by one Society with a single journal in its portfolio, which presents particular challenges. The decision to remain broad based in its content appeals to authors and readers across the breadth of antimicrobial chemotherapy rather than adding subject-specific publications to capture new developments in antiviral chemotherapy, for example. While this has drawbacks, there are also benefits in helping to sustain a readership that is more likely to remain eclectic in their understanding of the field.
Learning from advances in one field of therapeutics can, and should, influence developments in other areas. One example is the relatively early recognition of the advantages of combination therapy in the management of TB. This has influenced the exploration and application of synergistic regimens in the treatment of selected bacterial infections such as enterococcal endocarditis. However, its application to the management of viral infections such as HIV and hepatitis C infection was somewhat tardy, but, once adopted, rapidly proved to have therapeutic advantages as well as reducing the risk of resistance emerging.
In closing it is important to acknowledge the competitive streak required to drive a journal. This responsibility has become more and more intense in recent years with the 'publish or perish' culture that now prevails. The Journal has had a healthy rivalry with its competitors in the field, notably Antimicrobial Agents and Chemotherapy. Indeed, similar responsibilities have often led to EiCs sharing their experience without giving too much away about any future developments! Success, as judged by the increased impact factor, speaks volumes for the hard work of successive EiCs and, indeed, the editorial team as a whole. It has been a privilege to serve the Journal and the Society in this capacity.
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